Kai Rejeski, MD

Research Fellow
The Precision Cellular Therapy Laboratory
Publications
Jobs
Members

Kai Rejeski, MD

Research Fellow
Share
Share
Kai Rejeski

Kai Rejeski Is a German-American physician-scientist working as a postdoctoral research fellow in the Shouval Lab. Kai performed his doctoral research at the Yale University School of Medicine, where he studied splicing factor mutations in myelodysplastic syndromes. His interest in CAR T-cell therapy was piqued during a Sub-Internship in Pediatric Oncology at MSKCC. After graduating medical school at the University of Freiburg, he moved on to the LMU Munich, where he trained in hematology and was an active physician-scientist in the CAR-T group. In the Lab, he is currently working on projects related to mapping and dynamically modelling CAR T-cell related toxicities and exploring the potential of morphometric artificial intelligence techniques. The overall goal of his research lies in leveraging computational methods to better understand drivers of toxicities and to develop models that aid clinical decision-making and help improve the safety of novel cellular therapies.

Funding

Else-Kröner Clinician Scientist Fellowship, Bruno and Helene Jöster Foundation

Grants/Awards/Highlights

  • EHA/ASH Translational Research Training in Hematology (TRTH) Fellow (2024)
  • ASH Abstract Achievement Awards (2020-2023)
  • Young Investigator Award, German Society of Hematology and Medical Oncology (2023)
  • Lymphoma Clinical Research Award (Pfreundschuh Prize), German Lymphoma Alliance (2022)

Publications

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS, Theurich S, von Bergwelt-Baildon M, Ghobrial IM, Subklewe M, Perales MA, Rejeski K. Nat Med. 2024 Jul 8. doi: 10.1038/s41591-024-03084-6. Online ahead of print.

Immune effector cell-associated hematotoxicity after CAR T-cell therapy: from mechanism to management. Rejeski K, Jain MD, Shah N, Perales MA, Subklewe M. Lancet Haematol. 2024 May 8:S2352-3026(24)00077-2. Online ahead of print.

T-cell malignant neoplasms after chimeric antigen receptor T-cell therapy. Storgard R*, Rejeski K* (contributed equally), Perales MA, Goldman A, Shouval R. JAMA Oncol. 2024 Apr 18. Online ahead of print.

Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity. Liang EC*, Rejeski K* (contributed equally), Fei T, Albittar A, Huang JL, Portuguese AJ, Wu Q, Raj S, Subklewe M, Shouval R*, Gauthier J*. Bone Marrow Transplant. 2024 Apr 16. Online ahead of print.

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge WA, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Blood Adv. 2024 Apr 23;8(8):1857-1868.

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, Bergwelt M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Sci Adv. 2023 Sep 22;9(38):eadg3919.

Immune Effector Cell-Associated Hematotoxicity: EHA/EBMT Consensus Grading and Best Practice Recommendations. Rejeski K*, Subklewe M* (contributed equally), Aljurf M, Bachy E, Balduzzi AC, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jaeger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sanchez-Guijo FM, Sanchez-Ortega I, Schneidawind D, Schubert ML, Snowden JA, Thieblemont C, Topp MS, Zinzani PL, Gribben JG, Bonini C, Sureda A, Yakoub-Agha I. Blood. 2023 Sep 7;142(10):865-877

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. Rejeski K*, Hansen D* (contributed equally), Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M. J Hematol Oncol. 2023 Jul 31;16(1):88.

Influence of adipose tissue distribution, sarcopenia and nutritional status on clinical outcomes after CD19 CAR T-cell therapy. Rejeski K*, Cordas dos Santos D* (contributed equally), Parker NH, Bücklein V, Winkelmann M, Jhaveri K, Liu L, Trinkner P, Günther S, Karschnia P, Blumenberg V, Schmidt C, Kunz W, Bergwelt M, Jain M, Theurich S, Subklewe M. Cancer Immunol Res. 2023 Apr 11;CIR-22-0487.

The CAR-HEMATOTOX: a model for CAR T-cell-related hematological toxicity in relapsed/refractory large B-cell lymphoma. Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke F, Bergwelt M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain M, Subklewe M. Blood 2021 Dec 16;138(24):2499-2513

View a full listing of Kai Rejeski’s journal articles.